Kamada Ltd (KMDA) SEC filings

KMDANasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 11, 2026Score 5/30

$8.09−0.04 (-0.49%)

Close on Nov 13, 2026Market cap $466.68MP/E –Yield –

SEC filings

40 of Kamada's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Current report	6-K	Sep 30, 2026	Nov 9, 2026	SEC EDGAR
Current report	6-K	Nov 2, 2026	Nov 2, 2026	SEC EDGAR
Current report	6-K	Oct 6, 2026	Oct 6, 2026	SEC EDGAR
Current report	6-K	Oct 5, 2026	Oct 5, 2026	SEC EDGAR
Current report	6-K	Sep 17, 2026	Sep 17, 2026	SEC EDGAR
Current report	6-K	Sep 10, 2026	Sep 10, 2026	SEC EDGAR
Current report	6-K	Sep 3, 2026	Sep 3, 2026	SEC EDGAR
Current report	6-K	Aug 17, 2026	Aug 17, 2026	SEC EDGAR
Current report	6-K	Jun 30, 2026	Aug 12, 2026	SEC EDGAR
Current report	6-K	Aug 5, 2026	Aug 5, 2026	SEC EDGAR
Current report	6-K	Aug 5, 2026	Aug 5, 2026	SEC EDGAR
Current report	6-K	Jul 20, 2026	Jul 20, 2026	SEC EDGAR
Current report	6-K	Jul 13, 2026	Jul 13, 2026	SEC EDGAR
Current report	6-K	Jun 18, 2026	Jun 18, 2026	SEC EDGAR
Current report	6-K	Jun 1, 2026	Jun 1, 2026	SEC EDGAR
Current report	6-K	Mar 31, 2026	May 13, 2026	SEC EDGAR
Current report	6-K	May 6, 2026	May 6, 2026	SEC EDGAR
Current report	6-K	Mar 31, 2026	Mar 31, 2026	SEC EDGAR
Current report	6-K	Mar 26, 2026	Mar 26, 2026	SEC EDGAR
Current report	6-K	Mar 17, 2026	Mar 17, 2026	SEC EDGAR
Annual report	20-F	Dec 31, 2025	Mar 11, 2026	SEC EDGAR
Current report	6-K	Mar 11, 2026	Mar 11, 2026	SEC EDGAR
Current report	6-K	Mar 4, 2026	Mar 4, 2026	SEC EDGAR
Current report	6-K	Jan 7, 2026	Jan 7, 2026	SEC EDGAR
Current report	6-K	Dec 18, 2025	Dec 18, 2025	SEC EDGAR
Current report	6-K	Dec 10, 2025	Dec 10, 2025	SEC EDGAR
Current report	6-K	Dec 8, 2025	Dec 8, 2025	SEC EDGAR
Current report	6-K	Sep 30, 2025	Nov 10, 2025	SEC EDGAR
Current report	6-K	Nov 4, 2025	Nov 4, 2025	SEC EDGAR
Current report	6-K	Oct 23, 2025	Oct 23, 2025	SEC EDGAR
Current report	6-K	Sep 2, 2025	Sep 2, 2025	SEC EDGAR
Current report	6-K	Jun 30, 2025	Aug 13, 2025	SEC EDGAR
Current report	6-K	Aug 11, 2025	Aug 11, 2025	SEC EDGAR
Current report	6-K	Aug 6, 2025	Aug 6, 2025	SEC EDGAR
Current report	6-K	Jun 17, 2025	Jun 17, 2025	SEC EDGAR
Current report	6-K	Mar 31, 2025	May 14, 2025	SEC EDGAR
Current report	6-K	May 7, 2025	May 7, 2025	SEC EDGAR
Current report	6-K	May 5, 2025	May 5, 2025	SEC EDGAR
Current report	6-K	Mar 24, 2025	Mar 24, 2025	SEC EDGAR
Current report	6-K	Mar 19, 2025	Mar 19, 2025	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in Kamada's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is KMDA.

Compare: KMDA vs INCR · KMDA vs AKBA · KMDA vs LGND · KMDA vs RIGL · KMDA vs CYRX

Revenue growth13.2% · median 1.6%

Gross margin40.8% · median 78.9%

Operating margin14.5% · median -2.8%

Company	Revenue	Growth
RIGL	$288.21M	+2.2%
LGND	$253.83M	+1.0%
AKBA	$197.20M	-12.4%
CYRX	$192.44M	+11.8%
KMDA	$191.85M	+13.2%
INCR	–	–

Company

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 393
Held by institutions: 8.6%
Auditor: KOST FORER GABBAY & KASIERER
SEC CIK: 1567529

Advertisement
300 × 250

See a number that looks wrong?